Vertex Pharmaceuticals (VRTX -2.3%) and partner Alios BioPharma say they've decided to...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX -2.3%) and partner Alios BioPharma say they've decided to discontinue development of their hepatitis C virus drug candidate ALS-2158 due to disappointing results, but plan to begin Phase II testing of ALS-2200, an orally administered HCV drug regimen, by the end of the year. The companies hope to run one Phase II test of the drug in combination with Ribvarin, and a second testing with VRTX's recently approved HCV therapy Incivek.